why choose us

First received: November 24, 2023

Clinical Trial: RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Cancer Metastatic

Study Type: OBSERVATIONAL


Official Title: Real-world Evidence on Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Long-term Survival After Treatment With Liposomal Irinotecan (NALLONG)

Brief Summary: The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI

Read more